{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T21:59:39Z","timestamp":1771797579324,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,4,11]],"date-time":"2003-04-11T00:00:00Z","timestamp":1050019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology. Although HHV\u20108 (human herpesvirus type 8) has been suggested as a possible etiologic agent in a subpopulation of cases, appropriate treatment of the HHV\u20108 infection has not produced regression of the disease. Additionally, other treatment modalities, including steroids and various regimens of chemotherapy, do not consistently provide good control of the disease. Clinical signs and symptoms of the disease are primarily mediated by cytokines, especially interleukin\u20106 (IL\u20106). We report a case of multicentric Castleman's disease that responded dramatically to single agent thalidomide. A powerful cytokine disruptor, thalidomide may have good therapeutic efficacy in treating MCD and related cytokine\u2010mediated disorders. Am. J. Hematol. 73:48\u201353, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.10310","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T10:02:38Z","timestamp":1050314558000},"page":"48-53","source":"Crossref","is-referenced-by-count":42,"title":["Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide"],"prefix":"10.1002","volume":"73","author":[{"given":"Fa\u2010Chyi","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakil H.","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4"},{"key":"e_1_2_1_3_2","first-page":"636","article-title":"Multicentric Castleman's disease","volume":"20","author":"Peterson B","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.1998.0118"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0196"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/hupa.2001.21131"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/mp.53.2.69"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/593567"},{"key":"e_1_2_1_9_2","first-page":"19","article-title":"Human herpesvirus 8 (HHV8).II. Pathologenic role and sensitivity to antiviral drugs","volume":"57","author":"Boulanger E","year":"1999","journal-title":"Ann Biol Clin"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.1999.0598"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2000.1.133"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04777.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069.h8002069_2069_2073","article-title":"High levels of human herpesvirus 8 viral load, human interleukin\u20106, interleukin\u201010, and C reactive protein correlate with exacerbation of multicentric Castleman's disease in HIV\u2010infected patients","volume":"96","author":"Oksenhendler E","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2173"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1970114481"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124020-00002"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.2001.19.16.3593","article-title":"Thalidomide in the treatment of plasma cell malignancies","volume":"19","author":"Rajkumar V","year":"2001","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_18_2","first-page":"443","article-title":"Relationship between circulating interleukin\u201010 (IL\u201010) with interleukin\u20106 (IL\u20106) type cytokines (IL\u20106), interleukin\u201011 (IL\u201011), oncostatin M (OSM) and soluble interleukin\u20106 (IL\u20106) receptor (sIL\u20106) inpatients with multiple myeloma","volume":"11","author":"Urbanska\u2010Rys H","year":"2000","journal-title":"Eur Cytokine Netw"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(98)00010-1"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<670::AID-CNCR1369>3.0.CO;2-Q"},{"key":"e_1_2_1_22_2","first-page":"19","article-title":"Treatment of an abdominal form of Castleman's disease by chemotherapy","volume":"22","author":"See A","year":"1986","journal-title":"Ann Gastroenterol Hepatol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000187576"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950180416"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05366.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)03957-4"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008325114144"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/313979"},{"key":"e_1_2_1_29_2","first-page":"545","article-title":"A plasma cell variant of Castleman's disease treated successfully with cimetidine. Case report and review of the literature","volume":"16","author":"Barbounis V","year":"1996","journal-title":"Anticancer Res"},{"key":"e_1_2_1_30_2","first-page":"768","article-title":"Autoimmune hemolytic anemia associated with multicentric Castleman's disease with a 28\u2010year history","volume":"35","author":"Hisatake J","year":"1994","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900040305"},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman's disease by humanized anti\u2010interleukin\u20106 receptor antibody therapy","volume":"95","author":"Nishmoto N","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3473"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.4.1360.1360"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403033300904"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.637"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91413-9"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1202"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.10310","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.10310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:48:24Z","timestamp":1700225304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.10310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1002\/ajh.10310"],"URL":"https:\/\/doi.org\/10.1002\/ajh.10310","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,11]]}}}